Current and historical daily PE Ratio for Eton Pharmaceuticals Inc (
) from 2018 to May 26 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Eton Pharmaceuticals stock (ETON) PE ratio as of May 26 2024 is 89.5.
More Details
Eton Pharmaceuticals Inc (ETON) PE Ratio (TTM) Chart
Eton Pharmaceuticals Inc (ETON) PE Ratio (TTM) Historical Data
View and export this data going back to 2018. Start your Free Trial
Total 1237
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Eton Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-26 | 89.5 | 2024-03-22 | At Loss |
| 2024-05-24 | 89.5 | 2024-03-21 | At Loss |
| 2024-05-23 | 90.0 | 2024-03-20 | At Loss |
| 2024-05-22 | 91.5 | 2024-03-19 | At Loss |
| 2024-05-21 | 89.8 | 2024-03-18 | At Loss |
| 2024-05-20 | 91.0 | 2024-03-15 | At Loss |
| 2024-05-17 | 90.5 | 2024-03-14 | At Loss |
| 2024-05-16 | 91.3 | 2024-03-13 | At Loss |
| 2024-05-15 | 91.3 | 2024-03-12 | At Loss |
| 2024-05-14 | 90.8 | 2024-03-11 | At Loss |
| 2024-05-13 | 88.8 | 2024-03-08 | At Loss |
| 2024-05-10 | 85.8 | 2024-03-07 | At Loss |
| 2024-05-09 | 85.9 | 2024-03-06 | At Loss |
| 2024-05-08 | 93.0 | 2024-03-05 | At Loss |
| 2024-05-07 | 93.0 | 2024-03-04 | At Loss |
| 2024-05-06 | 93.8 | 2024-03-01 | At Loss |
| 2024-05-03 | 92.8 | 2024-02-29 | At Loss |
| 2024-05-02 | 93.8 | 2024-02-28 | At Loss |
| 2024-05-01 | 92.0 | 2024-02-27 | At Loss |
| 2024-04-30 | 87.5 | 2024-02-26 | At Loss |
| 2024-04-29 | 88.0 | 2024-02-23 | At Loss |
| 2024-04-26 | 86.3 | 2024-02-22 | At Loss |
| 2024-04-25 | 78.0 | 2024-02-21 | At Loss |
| 2024-04-24 | 80.3 | 2024-02-20 | At Loss |
| 2024-04-23 | 82.0 | 2024-02-16 | At Loss |
| 2024-04-22 | 81.3 | 2024-02-15 | At Loss |
| 2024-04-19 | 79.8 | 2024-02-14 | At Loss |
| 2024-04-18 | 76.5 | 2024-02-13 | At Loss |
| 2024-04-17 | 78.5 | 2024-02-12 | At Loss |
| 2024-04-16 | 79.8 | 2024-02-09 | At Loss |
| 2024-04-15 | 80.5 | 2024-02-08 | At Loss |
| 2024-04-12 | 85.5 | 2024-02-07 | At Loss |
| 2024-04-11 | 86.0 | 2024-02-06 | At Loss |
| 2024-04-10 | 85.8 | 2024-02-05 | At Loss |
| 2024-04-09 | 89.3 | 2024-02-02 | At Loss |
| 2024-04-08 | 86.3 | 2024-02-01 | At Loss |
| 2024-04-05 | 89.8 | 2024-01-31 | At Loss |
| 2024-04-04 | 89.0 | 2024-01-30 | At Loss |
| 2024-04-03 | 90.0 | 2024-01-29 | At Loss |
| 2024-04-02 | 92.0 | 2024-01-26 | At Loss |
| 2024-04-01 | 93.8 | 2024-01-25 | At Loss |
| 2024-03-28 | 93.8 | 2024-01-24 | At Loss |
| 2024-03-27 | At Loss | 2024-01-23 | At Loss |
| 2024-03-26 | At Loss | 2024-01-22 | At Loss |
| 2024-03-25 | At Loss | 2024-01-19 | At Loss |
Eton Pharmaceuticals Inc (ETON) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Eton Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US29772L1089
Description
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers